Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.289
Buy
RSI(14)
54.496
Neutral
STOCH(KDJ)(9,3,3)
68.266
Neutral
ATR(14)
3.369
High Vlolatility
CCI(14)
58.491
Neutral
Williams %R
33.984
Buy
TRIX(12,20)
0.267
Sell
StochRSI(14)
0.000
Sell
Search
Nektar Therapeutics
NKTRAdd to Watchlist
70.670USD
-0.780-1.09%
Close 07-31 16:00（ET）Quotes delayed by 15 min
2.39BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-1.09%
5 Days
-0.08%
1 Month
+9.75%
6 Months
+89.31%
Year to Date
+67.15%
1 Year
+207.80%
Key Figures
70.840Open
71.425High
497.24KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.69%Turnover Ratio
71.450Prev. Close
69.500Low
24.68MTurnover
LossP/E Static
3.61P/B
0.00%Div Yield TTM
-31.01%ROA
109.00052wk High
0.67Volume Ratio
-118.96MNet Profit
29.47MShares
-7.9223EPS TTM
1.17Beta
-53.60%ROE
7.99052wk Low
2.69%Amplitude
100.00%Gross Margin
2.39BMarket Cap
-0.58Reward/Risk
3.97%Risk Rate
TradingKey Stock Score of Nektar Therapeutics
Currency: USD Updated: 2026-07-31Key Insights
Nektar Therapeutics's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 101 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 153.22.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Nektar Therapeutics's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Nektar Therapeutics Highlights
StrengthsRisks
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Growing
The company is in a growing phase, with the latest annual income totaling USD 55.23M.
Undervalued
The company’s latest PE is -8.92, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 20.71M shares, increasing 6.00% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 16.51K shares of this stock.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
153.222
Target Price
+116.78%
Upside Space
Nektar Therapeutics News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
11
analysts
Buy
Current Rating
153.222
Target Price
+116.81%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Nektar Therapeutics
NKTR
11
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
70.984
Sell
MA10
69.783
Buy
MA20
70.008
Buy
MA50
65.781
Buy
MA100
72.250
Sell
MA200
63.027
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Nektar Therapeutics Info
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Ticker SymbolNKTR
CompanyNektar Therapeutics
CEORobin (Howard W)
Websitehttps://www.nektar.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Nektar Therapeutics (NKTR)?
The current price of Nektar Therapeutics (NKTR) is 70.67.
What is the symbol of Nektar Therapeutics?
The ticker symbol of Nektar Therapeutics is NKTR.
What is the 52-week high of Nektar Therapeutics?
The 52-week high of Nektar Therapeutics is 109.00.
What is the 52-week low of Nektar Therapeutics?
The 52-week low of Nektar Therapeutics is 7.99.
What is the market capitalization of Nektar Therapeutics?
The market capitalization of Nektar Therapeutics is 2.08B.
Is Nektar Therapeutics (NKTR) currently rated as Buy, Hold, or Sell?
According to analysts, Nektar Therapeutics (NKTR) has an overall rating of Buy, with a price target of 153.22.
What is the Earnings Per Share (EPS TTM) of Nektar Therapeutics (NKTR)?
The Earnings Per Share (EPS TTM) of Nektar Therapeutics (NKTR) is -9.73.